Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1387866rdf:typepubmed:Citationlld:pubmed
pubmed-article:1387866lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:1387866lifeskim:mentionsumls-concept:C0341439lld:lifeskim
pubmed-article:1387866lifeskim:mentionsumls-concept:C0276609lld:lifeskim
pubmed-article:1387866lifeskim:mentionsumls-concept:C1719822lld:lifeskim
pubmed-article:1387866lifeskim:mentionsumls-concept:C0522498lld:lifeskim
pubmed-article:1387866pubmed:issue4lld:pubmed
pubmed-article:1387866pubmed:dateCreated1992-10-15lld:pubmed
pubmed-article:1387866pubmed:abstractTextThe risk of developing a chronic carriage state after acute hepatitis B infection in adults was evaluated. Two hundred and eighty-nine HBV-susceptible heterosexual partners of acute hepatitis B patients were used to investigate the effectiveness of post-exposure immunoprophylaxis; 75 of them received hepatitis B vaccine, 72 hepatitis B hyperimmune globulin (HBIG), 71 vaccine plus HBIG and 71 placebo. Participants were interviewed, clinically examined and serum specimens were taken at 1, 3, 6 and 9 months after their first intervention. Serum samples were tested for ALT and HBV markers (HBsAg, anti-HBc and anti-HBs) using radio immunoassays. Forty-six (15.9%) of the heterosexual partners examined were infected; the incidence of HBV infections was higher among placebo (18.3%, 13/71) and HBIG (18.1%, 13/72) recipients compared to vaccine (16.0%, 12/75) and HBIG plus vaccine (11.3%, 8/71) recipients, but the differences were not statistically significant. Infections were significantly more often subclinical after immunoprophylaxis (p = 0.03). HBsAg was detected in all eight clinical and in 13 of the 38 subclinical cases. In the remaining 25 subclinical cases HBV infections were diagnosed by the development of anti-HBc and anti-HBs during the follow-up period. Finally, all 46 cases studied cleared the HBsAg.lld:pubmed
pubmed-article:1387866pubmed:languageenglld:pubmed
pubmed-article:1387866pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1387866pubmed:citationSubsetIMlld:pubmed
pubmed-article:1387866pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1387866pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1387866pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1387866pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1387866pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1387866pubmed:statusMEDLINElld:pubmed
pubmed-article:1387866pubmed:issn0300-8126lld:pubmed
pubmed-article:1387866pubmed:authorpubmed-author:Papaevangelou...lld:pubmed
pubmed-article:1387866pubmed:authorpubmed-author:RoumeliotouAAlld:pubmed
pubmed-article:1387866pubmed:issnTypePrintlld:pubmed
pubmed-article:1387866pubmed:volume20lld:pubmed
pubmed-article:1387866pubmed:ownerNLMlld:pubmed
pubmed-article:1387866pubmed:authorsCompleteYlld:pubmed
pubmed-article:1387866pubmed:pagination221-3lld:pubmed
pubmed-article:1387866pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:meshHeadingpubmed-meshheading:1387866-...lld:pubmed
pubmed-article:1387866pubmed:articleTitleChronic liver disease rarely follows acute hepatitis B in non-immunocompromised adults.lld:pubmed
pubmed-article:1387866pubmed:affiliationNational Centre for Viral Hepatitis, Athens School of Hygiene, Greece.lld:pubmed
pubmed-article:1387866pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1387866pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1387866pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:1387866pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed